SCHEMBL21550974

SCHEMBL21550974

CS(=O)(=O)OCc1cc(Oc2ccc(N3CCN(C(=O)O)CC3)nc2)cc(-c2cc(Cl)cc(Cl)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.42
▸ FURIN P09958 6/20 0.41
▸ ME2 P23368 6/20 0.38
▸ ME1 P48163 6/20 0.38
▸ ME3 Q16798 6/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ FAAH O00519 1/20 0.36
▸ MGLL Q99685 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.35
▸ PANK3 Q9H999 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ PPARD Q03181 1/20 0.35
▸ PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29891138 0.89 GPR119 (0.57) GPR119
SCHEMBL30931780 0.89 GPR119 (0.57) GPR119
SCHEMBL21551718 0.89 GPR119 (0.57) GPR119
SCHEMBL26077247 0.88 CNR2 (0.39) GPR119FURINTRPV1
SCHEMBL21551387 0.88 FURIN (0.55) GPR119FURIN
SCHEMBL21550952 0.82 FURIN (0.44) GPR119FURINME2ME1ME3
SCHEMBL21551096 0.82 FURIN (0.44) GPR119FURINME2ME1ME3
SCHEMBL21551431 0.81 KMT2A (0.46) FURINRAB9AMGLLPANK3
SCHEMBL21551454 0.81 FURIN (0.42) GPR119FURINKDM4EALDH1A1RAB9A
SCHEMBL28547910 0.79 FURIN (0.52) GPR119FURIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 — — US disclosed
EP-3790871-A1 FURIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-03-17 — — EP disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 GPR119 2318/4885FURIN 1/4885ME2 2267/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 GPR119 2318/4885FURIN 1/4885ME2 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback